Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

Abstract Aims To explore the associations between serum phenylacetylglutamine (PAGln) and chronic heart failure (HF). Methods and results Totally 956 subjects were enrolled consecutively from the Department of Cardiovascular Medicine, Ruijin Hospital. Baseline data were obtained from all participants, and 471 stable chronic HF subjects were followed up. Serum PAGln was analysed by liquid chromatography–tandem mass spectrometry. The association between PAGln and basic renal indicators was assessed by simple correlation analysis. Logistic regression analysis was conducted to measure the association between PAGln and HF risk. Event‐free survival was determined by Kaplan–Meier curves, and differences in survival were assessed using log‐rank tests. Cox proportional hazards analysis was used to assess the prognostic value of PAGln in HF. Serum PAGln levels were increased in patients with chronic HF (3.322 ± 8.220 μM vs. 1.249 ± 1.168 μM, P